A CONTROLLED RANDOMIZED DOUBLE-BLIND STUDY OF ANTILYMPHOBLAST GLOBULIN IN CADAVER RENAL TRANSPLANTATION

Publisher Website
Google Scholar
Abstract
The results of a controlled prospective randomized double-blind evaluation of antilymphoblast globulin [ALG] as an immunosuppressive adjunct to azathioprine and prednisone in cadaver renal transplantation are presented. There were 31 patients and 36 patients randomly assigned to therapeutic and control groups, respectively. ALG-treated patients experienced no major side-effects; delayed onset of rejection following transplantation (P < 0.005); reduced total number of rejection episodes (P < 0.05); fewer days in the hospital (P < 0.05); reduced cost of transplantation (P < 0.02); improved graft survival (P < 0.05); and patients survival equivalent to that of the control group. Apparently, ALG is safe, cost-effective and of immunologic benefit in cadaver renal transplantation.